JPX · 4519.T
Chugai Pharmaceutical Co., Ltd.
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
Loading market information…
JPX · 4694.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
BML, Inc.’s quoted price sits in the lower half of its reported 52-week range, 12.54% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
BML, Inc.’s forward annual dividend is ¥125 per share, paid semi-annual. The forward yield is 3.26% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
BML, Inc.’s next earnings report is currently expected on Nov 11, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BML, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:37 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2024 | Nov 8, 2024 | ¥44 | ¥35.78B+0.79% vs estimate |
|---|
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
¥6,651+¥180 (+2.78%)
Takeda Pharmaceutical Company Limited’s quoted price sits in the upper half of its reported 52-week range, 0.91% below the high.
¥26,210-¥120 (-0.46%)
HOYA Corporation’s quoted price sits in the lower half of its reported 52-week range, 13.78% below the high.
¥12,015-¥270 (-2.2%)
Otsuka Holdings Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.1% below the high.
¥2,754+¥137 (+5.21%)
Daiichi Sankyo Company, Limited’s quoted price sits in the lower half of its reported 52-week range, 30.19% below the high.
¥3,936+¥114 (+2.98%)
H.U. Group Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.46% below the high.
¥2,712+¥119 (+4.59%)
FALCO HOLDINGS Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 8.5% below the high.
¥1,236+¥9 (+0.73%)
Cosmo Bio Company,Limited’s quoted price sits in the lower half of its reported 52-week range, 16.82% below the high.
